Clinical trials in Walbrzych

51 clinical trials in Walbrzych, Poland. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in PolandBadaniaKliniczne.pl

Walbrzych at a glance

clinical trials

Paediatric trials0
Research sites0

Quick filters

51 trials in Walbrzych

Open in trial search

Acute myeloid leukaemia

Recruiting

Study on RVU120 and Venetoclax for Patients with Acute Myeloid Leukemia After Previous Treatment Failure

Registered drugNo placebo

Study on RVU120 and Venetoclax for Patients with Acute Myeloid Leukemia After Previous Treatment Failure

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Venetoclax
Sponsor:Ryvu Therapeutics S.A.

Contact Research Centre

Ductal adenocarcinoma of pancreas

Recruiting

A Study of Setidegrasib with Chemotherapy Drug Combination as First‑Line Treatment in Adults with KRAS G12D‑mutated Metastatic Pancreatic Cancer

Investigational

A Study of Setidegrasib with Chemotherapy Drug Combination as First‑Line Treatment in Adults with KRAS G12D‑mutated Metastatic Pancreatic Cancer

Investigational

Poland

Participants:18–64 years · 65+ years
Substances:ASP3082
Sponsor:Astellas Pharma Global Development Inc.

Contact Research Centre

Plasma cell myeloma refractory

Recruiting

Phase 3 Study Comparing JNJ-79635322 with Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma after 1‑3 Prior Treatments

InvestigationalNo placebo

Phase 3 Study Comparing JNJ-79635322 with Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma after 1‑3 Prior Treatments

InvestigationalNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Teclistamab
Sponsor:Janssen Cilag International

Contact Research Centre

Myelofibrosis+1

Recruiting

Study of pelabresib (DAK539) plus ruxolitinib versus placebo plus ruxolitinib in adult patients with myelofibrosis who are JAK‑inhibitor‑naive

Registered drug

Study of pelabresib (DAK539) plus ruxolitinib versus placebo plus ruxolitinib in adult patients with myelofibrosis who are JAK‑inhibitor‑naive

Registered drug

Poland

Participants:18–64 years · 65+ years
Substances:Ruxolitinib
Sponsor:Novartis Pharma AG

Contact Research Centre

Non-small cell lung cancer

Recruiting

Comparing sotorasib and pembrolizumab with chemotherapy for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drugNo placebo

Comparing sotorasib and pembrolizumab with chemotherapy for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:Amgen Inc.

Contact Research Centre

Hypergammaglobulinaemia benign monoclonal+1

Recruiting

A Study of Linvoseltamab in Adult Patients with High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma

Registered drugNo placebo

A Study of Linvoseltamab in Adult Patients with High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Dexamethasone
Sponsor:Regeneron Pharmaceuticals Inc.

Contact Research Centre

Follicle centre lymphoma follicular grade I, II - III

Recruiting

A study comparing odronextamab combined with chemotherapy versus rituximab combined with chemotherapy in adults with previously untreated follicular lymphoma

Registered drugNo placebo

A study comparing odronextamab combined with chemotherapy versus rituximab combined with chemotherapy in adults with previously untreated follicular lymphoma

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Cyclophosphamide
Sponsor:Regeneron Pharmaceuticals Inc.

Contact Research Centre

Acute myeloid leukaemia

Recruiting

Study of Revumenib and Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia with NPM1 Gene Mutation

Registered drug

Study of Revumenib and Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia with NPM1 Gene Mutation

Registered drug

Poland

Participants:0–17 years · 18–64 years · 65+ years
Substances:Cytarabine
Sponsor:Syndax Pharmaceuticals Inc.

Contact Research Centre

Chronic lymphocytic leukaemia+1

Recruiting

A Study Comparing DZD8586 to Other Treatments for Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Has Returned or Not Responded

Registered drugNo placebo

A Study Comparing DZD8586 to Other Treatments for Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Has Returned or Not Responded

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Idelalisib
Sponsor:Dizal Pharmaceutical Co. Ltd.

Contact Research Centre

Triple negative breast cancer

Recruiting

Study of sacituzumab tirumotecan, pembrolizumab and chemotherapy combination for early-stage triple-negative breast cancer or hormone receptor-low positive/HER2-negative breast cancer

Registered drugNo placebo

Study of sacituzumab tirumotecan, pembrolizumab and chemotherapy combination for early-stage triple-negative breast cancer or hormone receptor-low positive/HER2-negative breast cancer

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Non-small cell lung cancer+2

Recruiting

Study of THIO and cemiplimab compared to chemotherapy in patients with advanced non-small cell lung cancer who have received two previous treatments

Registered drugNo placebo

Study of THIO and cemiplimab compared to chemotherapy in patients with advanced non-small cell lung cancer who have received two previous treatments

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Cemiplimab
Sponsor:Maia Biotechnology Inc.

Contact Research Centre

Diffuse large B-cell lymphoma

Recruiting

Study Comparing Zilovertamab Vedotin with Drug Combination for Untreated Patients with Diffuse Large B-Cell Lymphoma

Registered drugNo placebo

Study Comparing Zilovertamab Vedotin with Drug Combination for Untreated Patients with Diffuse Large B-Cell Lymphoma

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Cyclophosphamide
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Other cities in Poland

The busiest research cities in the country

All 239 cities in Poland

Clinical research in Walbrzych

What the registry says about research in the country

01 Hematologic Malignancies

Groundbreaking research focusing on multiple myeloma and leukemia treatments, including novel combination therapies and targeted approaches for both newly diagnosed and relapsed/refractory cases.

Multiple Myeloma Studies
Acute Myeloid Leukemia Trials
Chronic Lymphocytic Leukemia Research

Several trials are evaluating innovative drug combinations to improve patient outcomes and survival rates.

02 Lymphoma Research

Comprehensive studies investigating treatments for various lymphoma types, with particular emphasis on follicular lymphoma and diffuse large B-cell lymphoma.

Novel Antibody Therapies
Combination Treatment Approaches
Comparative Effectiveness Studies

Research focuses on comparing new therapeutic options against current standard treatments.

03 Blood Disorders

Innovative trials examining treatments for myelodysplastic syndrome and myeloproliferative disorders, including studies of novel agents for anemia management.

Myelofibrosis Studies
Polycythemia Vera Research
Lower-Risk MDS Treatments

These studies aim to improve quality of life and treatment outcomes for patients with various blood disorders.

Back to Poland All countries